









Markets
/
Stocks
/
nasdaq-crdf
/

Cardiff Oncology Inc

CRDF

2.050USD

-0.110-5.09%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

136.38MMarket Cap

LossP/E TTM



Cardiff Oncology Inc

2.050

-0.110-5.09%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

137 / 506

Overall Ranking

245 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

10.417

Target Price

+382.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 76.94% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 683.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 17.37.

Overvalued

The company’s latest PE is -2.33, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 34.94M shares, increasing 2.21% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.73M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.06.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.72, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 121.00K, representing a year-over-year decrease of 25.77%, while its net profit experienced a year-over-year decrease of 18.37%.

Score

Industry at a Glance

Previous score

5.72

Change



Financials

6.20

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.09

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.63

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.46, which is 12.96% below the recent high of -2.78 and -39.68% above the recent low of -3.43.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 137/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.25, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Cardiff Oncology Inc is 10.00, with a high of 19.00 and a low of 3.50.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

10.417

Target Price

+408.13%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Cardiff Oncology Inc

CRDF

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.29, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.40 and the support level at 1.91, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.29

Change

-0.38

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.078

Neutral

RSI(14)

40.126

Neutral

STOCH(KDJ)(9,3,3)

36.447

Neutral

ATR(14)

0.124

Low Volatility

CCI(14)

-0.618

Neutral

Williams %R

59.459

Sell

TRIX(12,20)

-0.937

Sell

StochRSI(14)

54.255

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.052

Sell

MA10

2.079

Sell

MA20

2.105

Sell

MA50

2.717

Sell

MA100

2.983

Sell

MA200

3.331

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 52.52%, representing a quarter-over-quarter increase of 2.70%. The largest institutional shareholder is The Vanguard, holding a total of 3.73M shares, representing 5.60% of shares outstanding, with 63.17% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

3.12M

+36.34%

BlackRock Institutional Trust Company, N.A.

3.54M

+34.45%

William Blair & Company, L.L.C. (Research)

1.75M

+520.96%

Pfizer Inc

2.41M

Laurion Capital Management LP

916.21K

+58.81%

Geode Capital Management, L.L.C.

1.39M

+41.87%

Adage Capital Management, L.P.

1.45M

+11.82%

Acorn Capital Advisors, LLC

1.44M

Pace (Gary William)

1.06M

+0.74%

Millennium Management LLC

664.48K

+50.69%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.14, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.